4-ethyl-2-methyl-hexan-3-one | 40239-59-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-ethyl-2-methyl-hexan-3-one
• 英文别名: 4-Aethyl-2-methyl-hexan-3-on；4-Ethyl-2-methylhexan-3-one
• CAS: 40239-59-6
• 化学式: C₉H₁₈O
• 分子量: 142.241
• InChiKey: SPLBTWOVRQPGQN-UHFFFAOYSA-N

物化性质

• 沸点：
  170.3±8.0 °C(Predicted)
• 密度：
  0.812±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-乙基丁酸 在 氯化亚砜 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 4-ethyl-2-methyl-hexan-3-one
  参考文献：
  名称：

  Dubois, Jacques-Emile; Lion, Claude; Arouisse, Abdelmajid, Bulletin des Societes Chimiques Belges, 1984, vol. 93, # 12, p. 1083 - 1088

  摘要：

  DOI：

文献信息

• MODULATORS OF THE RELAXIN RECEPTOR 1
  申请人：The United States of America, as Represented by the Secretary, Dept. of Health & Human Services

  公开号：US20150119426A1

  公开（公告）日：2015-04-30

  Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R 1 , and R 2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.

  本文揭示了人类松弛素受体1的调节剂，例如，公式（I）中的A、R1和R2如本文所定义，这些调节剂在治疗哺乳动物松弛素受体1介导的人类健康方面，例如心血管疾病中是有用的。还公开了一种包含药用适宜载体和本公开的至少一种化合物的组合物，以及一种用于治疗介导人类松弛素受体1的哺乳动物健康方面的干预方法。
• PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES
  申请人：Blumberg Laura Cook

  公开号：US20110319422A1

  公开（公告）日：2011-12-29

  The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

  该发明提供了一种持续释放内酰胺、亚酰胺、酰胺、磺胺、碳酸酯或尿素含有母药的方法，通过向患者施用该发明的一种前药化合物的有效量，在向患者施用后，从前药中释放母药是持续释放的。适用于该发明方法的前药化合物是母药的不稳定结合物，通过羰基连接的前药基团进行衍生化。该发明的前药化合物可用于治疗任何需要内酰胺、亚酰胺、酰胺、磺胺、碳酸酯或尿素含有母药作为治疗的情况。
• Synthese de cetones aliphatiques encombrees
  作者：C. Lion、J.E. Dubois

  DOI：10.1016/s0040-4020(01)93497-0

  日期：1973.1

  4-dimethyl-2-oxazolines, 4, after hydrolysis of the intermediate enamine. Alkylation of the latter also permits the synthesis of α,α,α-trisubstituted ketones. α,α-Disubstituted ketones have been prepared by addition of organometallic reagents to 4,4-dimethyl-2-oxazolinium salts, 6. The efficiency of this method has been compared to that of other currently used methods.

  α，α-二取代的酮由中间体烯胺水解后有机锂化合物与取代的4,4-二甲基-2-恶唑啉4反应生成。后者的烷基化还允许合成α，α，α-三取代的酮。通过将有机金属试剂添加到4,4-二甲基-2-恶唑啉鎓盐6中，可以制备出α，α-二取代的酮。已将该方法的效率与其他当前使用的方法进行了比较。
• Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20150320875A1

  公开（公告）日：2015-11-12

  The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

  本发明提供了一种持续释放内酰胺、亚胺、酰胺、磺酰胺、氨基甲酸酯或尿素含量的母药的方法，通过向患者施用本发明的前药化合物的有效量，在患者体内释放母药的速率是持续释放的。适用于本发明方法的前药化合物是通过羰基偶联的前药基团衍生的母药的不稳定结合物。本发明的前药化合物可用于治疗任何需要内酰胺、亚胺、酰胺、磺酰胺、氨基甲酸酯或尿素含量的母药治疗的疾病。
• Hepatitis C Inhibitor Dipeptide Analogs
  申请人：BAILEY Murray D.

  公开号：US20090156822A1

  公开（公告）日：2009-06-18

  Compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

  式(I)的化合物：其中R1、R2、R3、R4、n和m的定义如本文所述。该化合物可用作HCV NS3蛋白酶的抑制剂。